Nvidia CEO Says There’s ‘0% Chance’ That World Will End in 2030
THE SO WHAT
A major chip CEO publicly assigning “0%” extinction risk to AI is as much a capital signal as a philosophical one — it reassures investors and customers that the buildout will continue. For operators, the takeaway is less about odds and more about planning horizons: assume multi-decade AI infra commitments, with safety debates running in parallel, not as a brake.
READ THE SOURCE
MORE FROM THE WIRE
Applied AIGoogle says its Gemini AI model hacked three other companies
Model evals are now crossing the line into real offensive operations—AI red-teaming is becoming indistinguishable from live-fire pen testing. If you run critical systems, assume your environment will be used as a testbed by someone’s model and tighten monitoring, legal posture, and vendor clauses around “research” access.
Applied AISources: Anthropic considers releasing a new AI model to counter OpenAI's momentum since Astra's launch, ahead of an IPO and after Amodei's call for a slowdown
Model cadence is now tied directly to capital markets—IPO timing and competitive optics are driving release schedules as much as safety rhetoric. For buyers, that means more frequent capability jumps but also more churn risk on APIs and pricing; lock in flexibility, not specific models.
Applied AI‘Almost Started a War’: US Military Nearly Boarded a Chinese Ship Based on Bad Intel From AI
An AI hallucination nearly triggering a boarding of a Chinese vessel is a live-fire example of why LLMs cannot sit unmediated in command chains. Any operator using AI for threat intel or targeting needs explicit doctrine: where AI can suggest, where humans must verify, and where AI is banned from the loop.
Applied AIAnthropic is operating a lab that conducts biology experiments
An AI lab running its own wet lab collapses the distance between model capability and real-world bio experimentation—governance, not just safety research, now has to live inside the same org chart as the tools. If you operate in bio or adjacent risk domains, assume leading labs will be direct R&D actors, not just model vendors, and update your dependency and oversight map accordingly.